Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
Development of effective drugs for the treatment or prevention of epidemic and pandemic influenza is important in order to reduce its impact. Adamantanes and neuraminidase inhibitors are two classes of anti-influenza drugs available for influenza therapy currently. However, emergence of resistance to these drugs has been detected, which raises concerns regarding their widespread use. In this review, resistance to the adamantanes and neuraminidase inhibitors will be discussed in relation to both epidemic and pandemic influenza viruses.
Hurt
Aeron C
AC
World Health Organization Collaborating Centre for Reference and Research on Influenza, Monash University, School of Applied Sciences, 45 Poplar Road, Parkville, Victoria 3052, Australia. aeron.hurt@influenzacentre.org
Ho
Hui-Ting
HT
Barr
Ian
I
D000218:Adamantane / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000378:metabolism; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D009439:Neuraminidase; D000218:Adamantane